Study: Decentralized and remote technology increases interest in clinical trials

Remote technology and decentralized clinical trials may increase patient participation, according to Published in the study Clothing network open.

Researchers surveyed 1,183 cancer patients and survivors about their interest in clinical trials and willingness to use remote interventions. Only 18% of cancers participated in clinical trials. Meanwhile, 77% said they would join a trial if the distance and frequency of visits were as easy to access as their regular care, and 47% said they would participate even if additional travel time or visits were needed.

Patients older than 55 years were significantly more likely to say that they would not participate in trials requiring travel longer than their usual place of care, while respondents from higher-income families were more likely to participate in the study that required additional effort.

More than 80% were willing to use remote interventions, such as delivering and receiving oral medications at home, providing electronically informed consent, and using apps or wearables. The study found that the use of remote options was associated with an increased desire to participate in clinical trials in all groups, especially those who showed the highest interest in trials, but also with respondents who initially said they did not want to be admitted to one. Judgment in any situation.

However, 86% of respondents said that it is important to have the option of personal inspection during a completely remote clinical trial.

“In this cross-sectional study of patients with cancer and survivors, most respondents have expressed a strong desire to participate in clinical trials of cancer. Changed, ”the researchers wrote.

“The use of remote technology and other decentralization tools that could reduce the need to travel to a trial site was associated with an increase in the chances of a self-reported patient participating in cancer trials.”

Why it matters

The authors of the study focused their survey on hypothetical clinical trials and did not measure whether interest matched actual trial participation. Meanwhile, clinical trials of cancer may vary in the intensity of the intervention, which may influence the decision to enroll patients. Respondents to a survey may also be more likely to show interest in a clinical trial than the general population.

However, the researchers said their survey shows that patients receive decentralized testing, which may help lower-income and older patients participate.

“Our data show that cancer patients and cancer survivors are more receptive to these technologies and tools, and that the use of the test context is associated with increased self-reporting possibilities if the technology or equipment reduces travel requirements. A trial site ৷ The degree to which you are more likely to participate in a trial varies by method, and the ability to have the option of a personal visit to a trial site whenever you wish was important, “they wrote.

Greater trend

Like other remote healthcare equipment, decentralized clinical trials COVID-19 gained traction during the epidemic. Diversity among clinical trial participants is also an ongoing concern, which according to some experts can be improved by adding virtual or remote flexibility.

In the meantime, there are several companies that offer decentralized clinical trial technology, including Curebase, Refine Health, Medable and Thread.

Leave a Reply

Your email address will not be published.